Samrat Pharmachem (BOM:530125) Cyclically Adjusted Revenue per Share: ₹755.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530125 Samrat Pharmachem Ltd BOM:530125
69 GF Score
Price ₹236.95
GF Value ₹362.16
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Samrat Pharmachem Cyclically Adjusted Revenue per Share?

Samrat Pharmachem BOM:530125 -3.60% 69 Cyclically Adjusted Revenue per Share is ₹755.02 as of Mar. 2026. GuruFocus rates BOM:530125 with a GF Score™ of 69/100 and a GF Value™ of ₹362.16 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Samrat Pharmachem's adjusted revenue per share for the three months ended in Mar. 2026 was ₹232.276. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹755.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Samrat Pharmachem's average Cyclically Adjusted Revenue Growth Rate was 13.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Samrat Pharmachem was 16.80% per year. The lowest was 14.60% per year. And the median was 15.70% per year.

As of today (2026-08-26), Samrat Pharmachem's current stock price is ₹236.95. Samrat Pharmachem's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹755.02. Samrat Pharmachem's Cyclically Adjusted PS Ratio of today is 0.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Samrat Pharmachem was 2.60. The lowest was 0.26. And the median was 0.66.


Samrat Pharmachem  (BOM:530125) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Samrat Pharmachem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=236.95/755.02
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Samrat Pharmachem was 2.60. The lowest was 0.26. And the median was 0.66.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Samrat Pharmachem Cyclically Adjusted Revenue per Share Related Terms


Samrat Pharmachem Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Samrat Pharmachem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Samrat Pharmachem Cyclically Adjusted Revenue per Share Chart

Samrat Pharmachem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 416.28 501.34 578.87 663.34 755.02

Samrat Pharmachem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 663.34 690.62 720.52 737.77 755.02

BOM:530125 vs DOW: Cyclically Adjusted Revenue per Share Comparison

For the Chemicals subindustry, Samrat Pharmachem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samrat Pharmachem Cyclically Adjusted PS Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Samrat Pharmachem's Cyclically Adjusted PS Ratio falls into.


BOM:530125
69GF Score
Samrat Pharmachem Ltd BOM:530125
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Samrat Pharmachem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Samrat Pharmachem's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=232.276/164.2724*164.2724
=232.276

Current CPI (Mar. 2026) = 164.2724.

Samrat Pharmachem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 69.254 105.961 107.365
201609 60.453 105.961 93.721
201612 58.747 105.196 91.738
201703 42.186 105.196 65.877
201706 65.391 107.109 100.290
201709 67.186 109.021 101.235
201712 81.248 109.404 121.996
201803 85.452 109.786 127.861
201806 82.344 111.317 121.517
201809 72.608 115.142 103.589
201812 88.908 115.142 126.845
201903 117.650 118.202 163.505
201906 114.786 120.880 155.991
201909 118.170 123.175 157.597
201912 113.442 126.235 147.624
202003 97.828 124.705 128.868
202006 114.021 127.000 147.484
202009 134.339 130.118 169.601
202012 177.496 130.889 222.766
202103 153.405 131.771 191.243
202106 153.067 134.084 187.529
202109 191.247 135.847 231.265
202112 179.164 138.161 213.025
202203 194.553 138.822 230.221
202206 280.030 142.347 323.162
202209 230.226 144.661 261.437
202212 271.260 145.763 305.706
202303 223.888 146.865 250.425
202306 186.260 150.280 203.602
202309 258.492 151.492 280.299
202312 198.755 152.924 213.504
202403 268.712 153.035 288.445
202406 261.821 155.789 276.078
202409 227.021 157.882 236.210
202412 205.957 158.323 213.697
202503 230.058 157.552 239.872
202506 244.590 159.755 251.506
202509 255.161 162.289 258.279
202512 205.662 163.281 206.911
202603 232.276 164.272 232.276

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹755.02 mean?
Samrat Pharmachem (BOM:530125) has a Cyclically Adjusted Revenue per Share of ₹755.02 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Samrat Pharmachem and its competitors.
Is Samrat Pharmachem's Cyclically Adjusted Revenue per Share too high?
Samrat Pharmachem's current Cyclically Adjusted Revenue per Share is ₹755.02. Overall, Samrat Pharmachem has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Cyclically Adjusted Revenue per Share compare to DOW?
Samrat Pharmachem's Cyclically Adjusted Revenue per Share of ₹755.02 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Chemicals company?
A good Cyclically Adjusted Revenue per Share depends on the Chemicals industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Samrat Pharmachem and its competitors. Samrat Pharmachem's current Cyclically Adjusted Revenue per Share is ₹755.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.16, compared to a current price of ₹236.95 — trading 34.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹755.02. Samrat Pharmachem's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Cyclically Adjusted Revenue per Share is ₹755.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?

Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued. The current stock price of ₹236.95 is trading 34.6% below its estimated GF Value™ of ₹362.16. GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.

Key valuation signals for BOM:530125:

  • Cyclically Adjusted Revenue per Share: ₹755.02
  • GF Value™: ₹362.16 vs. price of ₹236.95 (34.6% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Samrat Pharmachem Business Description

Address M. A. Road, 701/702, Business Square, Andheri (West), Mumbai, MH, IND, 400 058
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score

Get the complete analysis for BOM:530125

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹236.95
Price
₹362.16
GF Value